Using PSA Endpoints For Prostate Cancer Research

A new study from Columbia University Medical Center scientists at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival. Scientists looking to speed up the process of clinical trials have suggested that these biomarkers could be used to measure therapy efficacy........

Read The Full Article:
http://www.drilltools.org/294

Add to del.icio.us

Digg this

Post to Furl

Add to reddit

Add to myYahoo!